12:00 AM
May 03, 2004
 |  BioCentury  |  Emerging Company Profile

Saegis: Sae what?

Companies developing therapeutics for cognitive impairment have been hindered by the lack of a good animal model that mimics the disease process in humans. Saegis Pharmaceuticals Inc. believes it has found an approach to identify good targets and validate in-licensed compounds in preclinical models that will translate to success in developing drugs for Alzheimer's disease and a variety of other forms of cognitive impairment.

In November 2002, Saegis received an exclusive license from Johns Hopkins University for its Parallax technology, a drug discovery platform that compares the genes expressed in young, normal old, and memory impaired old rats. The parties have worked together to profile gene expression in aged rat models using both microarrays and behavioral tests for in vivo preclinical evaluation of candidate compounds.

About 100 genes appear to be important in the cognition of aging, of...

Read the full 678 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >